T-helper and T-regulatory cells modulation in head and neck squamous cell carcinoma

References

• Torre LA, Siege R, Ward E, Jemal A. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev 2016; 25(1):16-27; PMID:26667886; https://doi.org/10.1158/1055-9965.EPI-15-0578
   PubMed Web of Science ®Google Scholar
• Siegel R, Miller K, Jemal A. Cancer statistics, 2016. Cancer J Clin 2016; 66:7-30; PMID:26742998; https://doi.org/10.3322/caac.21332
   PubMed Web of Science ®Google Scholar
• Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis0ìì. Oncologist 2010; 15(9):994-1001; PMID:20798198; https://doi.org/10.1634/theoncologist.2009-0289
   PubMed Web of Science ®Google Scholar
• De Costa AM, Schuyler CA, Walker DD, Young MR. Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2012; 61(6):927-39; PMID:22116344; https://doi.org/10.1007/s00262-011-1154-8
   PubMed Web of Science ®Google Scholar
• Hartmann E1, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B, Giese T, Gires O, Endres S, Hartmann G. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003; 63(19):6478-87; PMID:14559840
   PubMed Web of Science ®Google Scholar
• Schuler PJ, Börger V, Bölke E, Habermehl D, Matuschek C, Wild CA, Greve J, Bas M, Schilling B, Bergmann C et al. Dendritic cell generation and CD4+ CD25high FOXP3+ regulatory t cells in human head and neck carcinoma during radio-chemotherapy. Eur J Med Res 2011; 16(2):57-62; PMID:21463982; https://doi.org/10.1186/2047-783X-16-2-57
   PubMed Web of Science ®Google Scholar
• Bron L, Jandus C, Andrejevic-Blant S, Speiser DE, Monnier P, Romero P, Rivals JP. Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. Int J Cancer 2013; 132(3):E85-93; PMID:22815199; https://doi.org/10.1002/ijc.27728
   PubMed Web of Science ®Google Scholar
• Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res 2000; 6:2794-802; PMID:10914726
   PubMed Web of Science ®Google Scholar
• Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun 2008; 12:8-10; PMID:18547033
   PubMedGoogle Scholar
• Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13(21):6301-11; PMID:17975141; https://doi.org/10.1158/1078-0432.CCR-07-1403
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Katou F, Ohtani H, Nakayama T, Yoshie O, Hashimoto K. Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109(5):744-52; PMID:20303300; https://doi.org/10.1016/j.tripleo.2009.12.015
   PubMed Web of Science ®Google Scholar
• Lim KP, Chun NA, Ismail SM, Abraham MT, Yusoff MN, Zain RB, Ngeow WC, Ponniah S, Cheong SC. CD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients. PLoS One 2014; 9(8):e103975; PMID:25153698; https://doi.org/10.1371/journal.pone.0103975
   PubMed Web of Science ®Google Scholar
• Grimm M, Feyen O, Hofmann H, Teriete P, Biegner T, Munz A, Reinert S. Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue. Tumour Biol 2016; 37(3):3807-16; PMID:26474587; https://doi.org/10.1007/s13277-015-4224-2
   PubMed Web of Science ®Google Scholar
• Wolf GT, Chepeha DB, Bellile E, Nguyen A, Thomas D, McHugh J. Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: A preliminary study. Oral Oncol 2015; 51(1):90-5; PMID:25283344; https://doi.org/10.1016/j.oraloncology.2014.09.006
   PubMed Web of Science ®Google Scholar
• Partlová S, Bouček J, Kloudová K, Lukešová E, Zábrodský M, Grega M, Fučíková J, Truxová I, Tachezy R, Špíšek R et al. Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. Oncoimmunology 2015; 4(1):e965570; PMID:25949860; https://doi.org/10.4161/21624011.2014.965570
   PubMed Web of Science ®Google Scholar
• Wan YY. Multi-tasking of helper T cells. Immunology 2010; 130(2):166-71; PMID:20557575; https://doi.org/10.1111/j.1365-2567.2010.03289.x
   PubMed Web of Science ®Google Scholar
• Becker Y. Molecular immunological approaches to biotherapy of human cancers – a review, hypothesis and implications. Anticancer Res 2006; 26(2A):1113-34; PMID:16619514
   PubMed Web of Science ®Google Scholar
• Chikamatsu K, Sakakura K, Takahashi G, Okamoto A, Furuya N, Whiteside TL, DeLeo AB, Masuyama K. CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer. Cancer Immunol Immunother 2009; 58(9):1441-8; PMID:19184003; https://doi.org/10.1007/s00262-009-0661-3
   PubMed Web of Science ®Google Scholar
• Kesselring R, Thiel A, Pries R, Wollenberg B. The number of CD161 positive Th17 cells are decreased in head and neck cancer patients. Cell Immunol 2011; 269(2):74-7; PMID:21570678; https://doi.org/10.1016/j.cellimm.2011.03.026
   PubMed Web of Science ®Google Scholar
• Sun W, Li WJ, Fu QL, Wu CY, Lin JZ, Zhu XL. Functionally distinct subsets of CD4+ regulatory T cells in patients with laryngeal squamous cell carcinoma are indicative of immune deregulation and disease progression. Oncol Rep 2015; 33(1):354-62; PMID:25333227; https://doi.org/10.3892/or.2014.3553
   PubMed Web of Science ®Google Scholar
• Sakakura K, Chikamatsu K, Takahashi K, Whiteside TL, Furuya N. Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2006; 55(2):151-9; PMID:15889251; https://doi.org/10.1007/s00262-005-0697-y
   PubMed Web of Science ®Google Scholar
• Eyigor M, Eyigor H, Osma U, Yilmaz MD, Erin N, Selcuk OT, Sezer C, Gultekin M, Koksoy S. Analysis of serum cytokine levels in larynx squamous cell carcinoma and dysplasia patients. Iran J Immunol 2014; 11(4):259-68; PMID:25549593; https://doi.org/ IJIv11i4A4
   PubMed Web of Science ®Google Scholar
• Gaur P, Singh AK, Shukla NK, Das SN. Inter-relation of Th1, Th2, Th17 and Treg cytokines in oral cancer patients and their clinical significance. Hum Immunol 2014; 75(4):330-7; PMID:24486578; https://doi.org/10.1016/j.humimm.2014.01.011
   PubMed Web of Science ®Google Scholar
• Kaskas NM, Moore-Medlin T, McClure GB, Ekshyyan O, Vanchiere JA, Nathan CA. Serum biomarkers in head and neck squamous cell cancer. Otolaryngol Head Neck Surg 2014; 140(1):5-11; PMID:24232368; https://doi.org/10.1001/jamaoto.2013.5688
   PubMed Web of Science ®Google Scholar
• Sparano A, Lathers DM, Achille N, Petruzzelli GJ, Young MR. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2004; 131(5):573-6; PMID:15523428; https://doi.org/10.1016/j.otohns.2004.03.016
   PubMed Web of Science ®Google Scholar
• Jebreel A1, Mistry D, Loke D, Dunn G, Hough V, Oliver K, Stafford N, Greenman J. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol 2007; 121(3):246-52; PMID:17040593; https://doi.org/10.1017/S0022215106002428
   PubMed Web of Science ®Google Scholar
• Alhamarneh O, Agada F, Madden L, Stafford N, Greenman J. Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head Neck 2011; 33(3):415-23; PMID:20645289; https://doi.org/10.1002/hed.21464
   PubMed Web of Science ®Google Scholar
• Lathers DM1, Achille NJ, Young MR. Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol 2003; 64(12):1160-6; PMID:14630398; https://doi.org/10.1016/j.humimm.2003.08.024
   PubMed Web of Science ®Google Scholar
• Kesselring R, Thiel A, Pries R, Trenkle T, Wollenberg B. Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer 2010; 103(8):1245-54; PMID:20877351; https://doi.org/10.1038/sj.bjc.6605891
   PubMed Web of Science ®Google Scholar
• Li C, Zhao Y, Zhang W, Zhang W. Increased prevalence of T(H)17 cells in the peripheral blood of patients with head and neck squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 112(1):81-9; PMID:21458322; https://doi.org/10.1016/j.tripleo.2010.11.032
   PubMed Web of Science ®Google Scholar
• Young MR, Levingston CA, Johnson SD. Treatment to sustain a Th17-type phenotype to prevent skewing toward Treg and to limit premalignant lesion progression to cancer. Int J Cancer 2016; 138(10):2487-98; PMID:26756968; https://doi.org/10.1002/ijc.29989
   PubMed Web of Science ®Google Scholar
• Woodford D, Johnson SD, De Costa AM, Young MR. An inflammatory cytokine milieu is prominent in premalignant oral lesions, but subsides when lesions progress to squamous cell carcinoma. J Clin Cell Immunol 2014; 5(3):230; PMID:25419481; https://doi.org/10.4172/2155-9899.1000230
   PubMedGoogle Scholar
• Punt S, Dronkers EA, Welters MJ, Goedemans R, Koljenović S, Bloemena E, Snijders PJ, Gorter A, van der Burg SH, Baatenburg de Jong RJ, et al. A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequency. Cancer Immunol Immunother 2016; 65(4):393-403; PMID:26899388; https://doi.org/10.1007/s00262-016-1805-x
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Jackson EK. Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease. Front Immunol 2013; 4:212; PMID:23898333; https://doi.org/10.3389/fimmu.2013.00212
   PubMed Web of Science ®Google Scholar
• Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005; 92(5):913-20; PMID:15714205; https://doi.org/10.1038/sj.bjc.6602407
   PubMed Web of Science ®Google Scholar
• Yu N, Li X, Song W, Li D, Yu D, Zeng X, Li M, Leng X, Li X. CD4(+)CD25 (+)CD127 (low) T cells: a more specific Treg population in human peripheral blood. Inflammation 2012; 35(6):1773-80; PMID:22752562; https://doi.org/10.1007/s10753-012-9496-8
   PubMed Web of Science ®Google Scholar
• Schipmann S, Wermker K, Schulze HJ, Kleinheinz J, Brunner G. Cutaneous and oral squamous cell carcinoma-dual immunosuppression via recruitment of FOXP3+ regulatory T cells and endogenous tumour FOXP3 expression? J Craniomaxillofac Surg 2014; 42(8):1827-33; PMID:25087653; https://doi.org/10.1016/j.jcms.2014.06.022
   PubMed Web of Science ®Google Scholar
• Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res 2017; 27(1):109-118; PMID:27995907; https://doi.org/10.1038/cr.2016.151
   PubMed Web of Science ®Google Scholar
• Al-Qahtani D1, Anil S, Rajendran R. Tumour infiltrating CD25+ FoxP3+ regulatory T cells (Tregs) relate to tumour grade and stromal inflammation in oral squamous cell carcinoma. J Oral Pathol Med 2011; 40(8):636-42; PMID:21352381; https://doi.org/10.1111/j.1600-0714.2011.01020.x
   PubMed Web of Science ®Google Scholar
• Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9(12):4404-8; PMID:14555512
   PubMed Web of Science ®Google Scholar
• Liang YJ1, Liu HC, Su YX, Zhang TH, Chu M, Liang LZ, Liao GQ. Foxp3 expressed by tongue squamous cell carcinoma cells correlates with clinicopathologic features and overall survival in tongue squamous cell carcinoma patients. Oral Oncol 2011; 47(7):566-70; PMID:21641272; https://doi.org/10.1016/j.oraloncology.2011.04.017
   PubMed Web of Science ®Google Scholar
• Bron L, Jandus C, Andrejevic-Blant S, Speiser DE, Monnier P, Romero P, Rivals JP. Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. Int J Cancer 2013; 132(3):E85-93; PMID:22815199; https://doi.org/10.1002/ijc.27728
   PubMed Web of Science ®Google Scholar
• Jie HB, Gildener-Leapman N, Li J, Srivastava RM, Gibson SP, Whiteside TL, Ferris RL. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 2013; 109(10):2629-35; PMID:24169351; https://doi.org/10.1038/bjc.2013.645
   PubMed Web of Science ®Google Scholar
• Wang WL, Chang WL, Yang HB, Chang IW, Lee CT, Chang CY, Lin JT, Sheu BS. Quantification of tumor infiltrating Foxp3+ regulatory T cells enables the identification of high-risk patients for developing synchronous cancers over upper aerodigestive tract. Oral Oncol 2015; 51(7):698-703; PMID:25958829; https://doi.org/10.1016/j.oraloncology.2015.04.015
   PubMed Web of Science ®Google Scholar
• Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006; 12(2):465-72; PMID:16428488; https://doi.org/10.1158/1078-0432.CCR-05-1886
   PubMed Web of Science ®Google Scholar
• Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016; 1(17):e89829; PMID:27777979; https://doi.org/10.1172/jci.insight.89829
   PubMed Web of Science ®Google Scholar
• Wansom D, Light E, Worden F, Prince M, Urba S, Chepeha DB, Cordell K, Eisbruch A, Taylor J, D'Silva N et al. Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 2010; 136:1267-73; PMID:21173378; https://doi.org/10.1001/archoto.2010.211
   PubMedGoogle Scholar
• Sun W, Li WJ, Wei FQ, Wong TS, Lei WB, Zhu XL, Li J, Wen WP. Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma. Oncotarget 2016; 7(25):37714-27; PMID:27177223; https://doi.org/10.18632/oncotarget.9265
   PubMed Web of Science ®Google Scholar
• Baatar D, Olkhanud P, Sumitomo K, Taub D, Gress R, Biragyn A. Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4− Tregs, regulate effector T cells using FasL. J Immunol 2007; 178:4891-900; PMID:17404270; https://doi.org/10.4049/jimmunol.178.8.4891
   PubMed Web of Science ®Google Scholar
• Valzasina B, Piconese S, Guiducci C, Colombo MP. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res 2006; 66:4488-95; PMID:16618776; https://doi.org/10.1158/0008-5472.CAN-05-4217
   PubMed Web of Science ®Google Scholar
• Gasparoto TH, de Souza Malaspina TS, Benevides L, de Melo EJ Jr, Costa MR, Damante JH, Ikoma MR, Garlet GP, Cavassani KA, da Silva JS et al. Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment. Cancer Immunol Immunother 2010; 59(6):819-28; PMID:20012605; https://doi.org/10.1007/s00262-009-0803-7
   PubMed Web of Science ®Google Scholar
• Read S, Greenwald R, Izcue A, Robinson N, Mandelbrot D, Francisco L, Sharpe AH. Powrie f blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 2006; 177(7):4376-83; PMID:16982872; https://doi.org/10.4049/jimmunol.177.7.4376
   PubMed Web of Science ®Google Scholar
• de Oliveira Bravo M, Carvalho JL, Saldanha-Araujo F. Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression. Purinergic Signal 2016; 12(4):595-609; PMID:27557887; https://doi.org/10.1007/s11302-016-9529-0
   PubMed Web of Science ®Google Scholar
• Nikolova M1, Carriere M, Jenabian MA, Limou S, Younas M, Kök A, Huë S, Seddiki N, Hulin A, Delaneau O et al. CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog 2011; 7(7):e1002110; PMID:21750674; https://doi.org/10.1371/journal.ppat.1002110
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Das SN. Thiodigalactoside shows antitumour activity by beta-galactoside-binding protein and regulatory T cells inhibition in oral squamous cell carcinoma. Oral Dis 2016; 22(5):445-53; PMID:27004748; https://doi.org/10.1111/odi.12479
   PubMed Web of Science ®Google Scholar
• Economopoulou P, Perisanidis C, Giotakis EI, Psyrri A. The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): Anti-tumor immunity and clinical applications. Ann Transl Med 2016; 4(9):173; PMID:27275486; https://doi.org/10.21037/atm.2016.03.34
   PubMed Web of Science ®Google Scholar
• Wolf GT, Fee WE, Dolan RW, Moyer JS, Kaplan MJ, Spring PM, Suen J, Kenady DE, Newman JG, Carroll WR et al. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck 2011; 33(12):1666-74; PMID:21284052; https://doi.org/10.1002/hed.21660
   PubMed Web of Science ®Google Scholar
• Egan JE, Quadrini KJ, Santiago-Schwarz F, Hadden JW, Brandwein HJ, Signorelli KL. IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro. J Immunother 2007; 30(6):624-33; PMID:17667526; https://doi.org/10.1097/CJI.0b013e3180691593
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. ClinicalTrials.gov database, a service of the U.S. National Institutes of Health. https://clinicaltrials.gov/
   Google Scholar
• Starr P. Encouraging results for pembrolizumab in head and neck cancer. Am Health Drug Benefits 2015; 8:16; PMID:26380607
   PubMedGoogle Scholar
• Chiakamatsu K, Sakakura K, Whiteside TL, Furuya N, Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck 2017; 29(2):120–7; https://doi.org/10.1002/hed.20490
   Web of Science ®Google Scholar